Wells Fargo Gives Sunesis Pharma (SNSS) Higher Rating; Lam Research (LRCX)’s Sentiment Is 1.02

December 11, 2017 - By Clifton Ray

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits worldwide. The company has market cap of $30.20 billion. The firm offers thin film deposition products, including SABRE electrochemical deposition products for copper damascene manufacturing; ALTUS systems to deposit conformal atomic layer films for tungsten metallization applications; VECTOR plasma-enhanced chemical vapor deposition and atomic layer deposition systems to deposit oxides, nitrides, and carbides for hardmasks, multiple patterning films, anti-reflective layers, multi-layer stack films, and diffusion barriers; and Striker atomic layer deposition systems that deliver conformal dielectric films for spacer patterning and liner applications in various advanced memory and logic structures. It has a 17.02 P/E ratio. The Company’s thin film deposition products also comprise SPEED high-density plasma CVD products for applications in shallow trench isolation, pre-metal dielectrics, inter-layer dielectrics, inter-metal dielectrics, and passivation layers; and SOLA ultraviolet thermal processing products for treatment of back-end-of-line (BEOL) low-k dielectric films and front-end-of-line silicon nitride strained films.

Among 5 analysts covering Sunesis Pharmaceuticals (NASDAQ:SNSS), 1 have Buy rating, 1 Sell and 3 Hold. Therefore 20% are positive. Sunesis Pharmaceuticals has $7.0 highest and $1 lowest target. $3.67’s average target is 47.98% above currents $2.48 stock price. Sunesis Pharmaceuticals had 9 analyst reports since July 24, 2015 according to SRatingsIntel. TH Capital downgraded the shares of SNSS in report on Friday, July 24 to “Sell” rating. Wells Fargo downgraded Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) on Tuesday, December 5 to “Market Perform” rating. The stock has “Outperform” rating by Wells Fargo on Friday, July 29. The firm has “Hold” rating by Cantor Fitzgerald given on Thursday, July 27. Cowen & Co downgraded the shares of SNSS in report on Friday, July 24 to “Market Perform” rating. The company was downgraded on Friday, July 24 by Cantor Fitzgerald. Cantor Fitzgerald maintained the stock with “Hold” rating in Tuesday, July 18 report. Oppenheimer initiated the shares of SNSS in report on Monday, November 20 with “Buy” rating.

The stock decreased 1.43% or $2.7 during the last trading session, reaching $186.46. About 3.48M shares traded or 40.53% up from the average. Lam Research Corporation (LRCX) has risen 107.86% since December 11, 2016 and is uptrending. It has outperformed by 91.16% the S&P500.

Ratings analysis reveals 83% of Lam Research’s analysts are positive. Out of 6 Wall Street analysts rating Lam Research, 5 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $110.0 while the high is $125.0. The stock’s average target of $118.75 is -36.31% below today’s ($186.46) share price. LRCX was included in 6 notes of analysts from October 12, 2016. The firm has “Outperform” rating given on Friday, January 13 by RBC Capital Markets. Stifel Nicolaus maintained Lam Research Corporation (NASDAQ:LRCX) rating on Thursday, October 20. Stifel Nicolaus has “Buy” rating and $110.0 target. The company was upgraded on Monday, December 19 by Goldman Sachs. The rating was downgraded by Pacific Crest to “Sector Weight” on Wednesday, October 12. The firm has “Buy” rating given on Thursday, October 20 by Needham. The firm has “Outperform” rating given on Thursday, January 26 by Cowen & Co.

Analysts await Lam Research Corporation (NASDAQ:LRCX) to report earnings on January, 24. They expect $3.67 EPS, up 63.84% or $1.43 from last year’s $2.24 per share. LRCX’s profit will be $594.33M for 12.70 P/E if the $3.67 EPS becomes a reality. After $3.46 actual EPS reported by Lam Research Corporation for the previous quarter, Wall Street now forecasts 6.07% EPS growth.

Oaktop Capital Management Ii L.P. holds 7.63% of its portfolio in Lam Research Corporation for 294,504 shares. Rgm Capital Llc owns 522,062 shares or 7.5% of their US portfolio. Moreover, Oakmont Corp has 6.47% invested in the company for 240,160 shares. The California-based Cypress Funds Llc has invested 6.45% in the stock. Sensato Investors Llc, a California-based fund reported 144,761 shares.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company has market cap of $84.94 million. The firm is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia . It currently has negative earnings. It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com